Update May 18, 2017: I am in the process of writing an article on EASL 2017 for our newsletter. After reviewing other similar presentations and abstracts I believe this article and study is flawed and unnecessarily scary. I originally pointed out that patients in this study had advanced liver disease (which is true), but additionally, it was a small patient population and contradicts other studies with larger patient populations, longer patient follow-up periods and ones that include both direct-acting antiviral medications and interferon-based therapies. Please read the upcoming June 2017 HCV Advocate newsletter for more information. -Alan for www.hcvadvocate.org
Note: This is really important information but read the entire article since the reoccurrence occurred in patients with advanced liver disease. That being said, it is important that people with cirrhosis should be followed carefully after being cured and should not be a reason should not be a reason to avoid HCV treatment. Alan
In updated results presented at the 2017 International Liver Congress, Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma (HCC) recurrence following treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection.
Maria Reig MD, PhD, presented data updating results published last year evaluating increased rates of tumor recurrence in patients following successful treatment for HCC and within months of exposure to DAA treatment. At median follow-up of 12.4 months post-initiation of DAA therapy, 77 patients complete response (CR) following HCC treatment. Of those, 24 patients (31.2%) experienced recurrence and 5 patients (6.5%) died.
“These data indicate that there needs to be further research conducted in this area, clarifying the mechanism for the association between liver cancer recurrence and DAA therapy,” Reig said. “Our study offers further support to previous findings that there is an unexpected high recurrence rate of hepatocellular carcinoma associated with DAAs, and that this association may result in a more aggressive pattern of recurrence and faster tumour progression.”
Share This Page